Please assess the completion status of the following clinical trial:

Trial Title: Losartan to Improve Hip Microfracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Underwent primary hip arthroscopy~* Underwent baseline quantitative MRI at The Steadman Clinic (TSC)~* Single, localized, grade 3 or 4 cartilage lesion of the acetabulum or femoral head treated with Bone Marrow Stimulation (BMS; i.e. microfracture)~* Aged 18-60 at time of surgery~* Tonnis grade 1 or less~Exclusion Criteria:~* Two or more cartilage lesions of grade 3 or 4~* Less than 2 mm of minimal hip joint space~* Osteoarthritis or diffuse change of cartilage~* Non-English speaking~* Prior hip surgery on operative hip~* Pre-existing bony deformity caused by previous fracture(s)~* Synovial chondromatosis~* Pigmented Villonodular Synovitis (PVNS)~* Dysplasia (center edge angle \<20 degrees)~* History of Avascular Necrosis (AVN), Perthes disease, or slipped capital femoral epiphysis (SCFE)~* Inflammatory arthritis or other arthritis caused by autoimmune disease~* Patients allergic to any active or inactive ingredient of losartan~* Patients taking medication with known losartan interaction, including phenobarbital, rifampin, and fluconazole.~* Subjects that are currently taking losartan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Losartan (Type: EXPERIMENTAL): 12.5mg Losartan capsules, oral administration, twice daily (25mg total per day), taken for 30 consecutive days starting on the evening of the second post-surgery day.
- Placebo (Type: PLACEBO_COMPARATOR): Appearance-matched placebo capsules, oral administration, twice daily, taken for 30 consecutive days starting on the evening of the second post-surgery day.

Based on this trial design, predict the completion outcome and termination type (if applicable).